A Randomized, Placebo-Controlled, Double-Blind Study To Evaluate The Effect Of Sage-718 On Cognitive Function In Participants With Huntington’S Disease
Posted Date: Jul 7, 2022
- Investigator: Andrew Duker
- Specialties: Movement Disorders, Neurology
- Type of Study: Drug
This is a randomized, placebo-controlled, double-blind study to evaluate the cognitive effects, safety, tolerability, and PK of SAGE-718 in participants with premanifest or early manifest HD. Participants will be adults with genetically confirmed expansion of the huntingtin gene CAG trinucleotide repeat at screening who meet diagnostic criteria detailed in the inclusion criteria below (including UHDRS scores and CAG-Age-Product [CAP] scores within specific ranges).
Criteria:
Eligibility Criteria: Inclusion Criteria Participants Must Meet All The Following Criteria To Qualify For Participation In This Study: 1. Be Capable Of Providing Informed Consent, In The Opinion Of The Investigator. 2. Have Signed An Informed Consent For
Keywords:
Huntington’S, Cognitive
For More Information:
Chandana Ravipati
5135583345
ravipaca@ucmail.uc.edu